Trial Profile

BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axalimogene filolisbac (Primary) ; Fluorouracil; Mitomycin
Indications Anal cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Mar 2018 Status changed from active, no longer recruiting to discontinued.
25 Jan 2018 Results were presented in an Advaxis media release.
25 Jan 2018 According to an Advaxis media release, data from this investigator-initiated study were published in the International Journal of Radiation Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com